Media headlines about Lion Biotechnologies (NASDAQ:IOVA) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Lion Biotechnologies earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.0456844155461 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several equities analysts have issued reports on IOVA shares. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Lion Biotechnologies in a research note on Wednesday, September 13th. Jefferies Group LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Lion Biotechnologies in a research note on Tuesday, September 5th. Oppenheimer Holdings Inc. reissued a “buy” rating and issued a $13.00 price objective on shares of Lion Biotechnologies in a research note on Tuesday, September 26th. Chardan Capital reissued a “buy” rating and issued a $20.00 price objective on shares of Lion Biotechnologies in a research note on Friday, September 1st. Finally, Zacks Investment Research raised shares of Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $8.25 price objective on the stock in a research note on Tuesday, October 17th. Ten analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $14.09.
Shares of Lion Biotechnologies (IOVA) traded up 4.79% during midday trading on Monday, hitting $7.65. 510,715 shares of the company’s stock traded hands. Lion Biotechnologies has a 52 week low of $4.45 and a 52 week high of $8.60. The stock’s market cap is $547.18 million. The company has a 50 day moving average of $7.54 and a 200 day moving average of $6.50.
TRADEMARK VIOLATION NOTICE: This report was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.com-unik.info/2017/10/30/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-lion-biotechnologies-iova-stock-price.html.
Lion Biotechnologies Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
What are top analysts saying about Lion Biotechnologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Lion Biotechnologies Inc. and related companies.